Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T60628
(Former ID: TTDI02098)
|
|||||
Target Name |
Kappa myeloma antigen (KMA)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Malignant haematopoietic neoplasm [ICD-11: 2B33] | |||||
BioChemical Class |
Kappa myeloma antigen
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | MDX-1097 | Drug Info | Phase 2 | Haematological malignancy | [2] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43. | |||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025289) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.